Report cover image

Asia Pacific Cell and Gene Therapy Market Size and Forecast (2021 - 2031), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Type [Cell Therapy (Allogeneic, Autologous, Viral Vectors), and Gene Therapy (Non-viral Vector

Publisher The Insight Partners
Published Dec 08, 2025
Length 229 Pages
SKU # TIP20709004

Description

According to our new research study on “Asia Pacific Cell And Gene Therapy Market Forecast to 2031 –Regional Analysis – by Type, Service, Scale, Service Providers, Transfection Reagents, and End User,” the market is anticipated to grow from US$ 1.51 billion in 2024 to US$ 8.98 billion by 2031; the market is expected to register a CAGR of 29.1% from 2025 to 2031. The Asia Pacific cell and gene therapy market growth are attributed to the increasing prevalence of chronic and genetic diseases, supportive government initiatives, and the rapid popularity of outsourcing cell and gene therapy manufacturing.

Cell therapy provides the needed working cells for repair or immune defense of the body, whereas gene therapy either adds new genetic instructions or changes the existing ones to fix the disorder or to change the cell's nature. As a result of their combination, the targeted treatments, which are in most cases of a personal nature, can be used for such diseases as cancer, genetic disorders, autoimmune diseases, and degenerative conditions.

The Asia Pacific cell and gene therapy market is categorized into the Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, the Philippines, Vietnam, and the Rest of Asia Pacific. The rising prevalence of genetic disorders, cancers, and chronic diseases has created a strong need for advanced treatment modalities, motivating investment in cell and gene therapy (CGT) research and commercialization. Governments across countries such as China, Japan, South Korea, and Singapore are promoting biotechnology innovation through funding, fast-track regulatory pathways, and infrastructure development, accelerating clinical trial approvals and product launches. Cost-effective manufacturing capabilities and a large, diverse patient population make APAC an attractive hub for global pharmaceutical and biotech companies to conduct trials and expand market access. Increasing awareness of personalized medicine and improvements in healthcare infrastructure contribute to early adoption of advanced therapies. As academic institutions, research organizations, and hospitals collaborate more closely, translational research and technology transfer accelerate, boosting innovation.

According to GLOBOCAN 2022 data from the International Agency for Research on Cancer, China reported approximately 4,824,700 new cancer cases and 2,574,200 cancer deaths. The rising prevalence of cancer is underscoring the urgent need for targeted therapies, such as CAR-T cells. According to a report by China's Center for Drug Evaluation (CDE) under the National Medical Products Administration (NMPA) in June 2025, 115 clinical trials for CGT products were registered in 2024, representing a 42% increase from 2023. Companies such as Neukio are exploring allogeneic immune cell technologies, such as iPSC-CAR-NK cells, to address current limitations in cell therapy. These technological advancements enhance the efficiency and scalability of CGT manufacturing, driving the demand for specialized CDMO services. OBiO Technology, a leading CDMO in China specializing in cell and gene therapies, operates 15 GMP-certified vector production lines and 20 GMP cell therapy production lines.

India faces a staggering burden of diseases amenable to cell and gene therapies, particularly cancers and rare genetic disorders, driving urgent innovation in this sector. According to GLOBOCAN 2022 projections from the International Agency for Research on Cancer (IARC), the country recorded 1,413,316 new cancer cases in 2022, contributing to over 900,000 deaths in the same year. Rare genetic diseases affect approximately 70 million Indians, exacerbated by high rates of consanguinity and endogamy that elevate recessive mutation prevalence, with over 450 such conditions documented nationally by the Translational Genomics Institute of Genetics and Society (TIGS). Hemophilia impacts nearly 48,000 individuals with type A alone, based on World Federation of Hemophilia estimates.

The US Food and Drug Administration, National Institute of Health, Asian National Cancer Centers Alliance (ANCCA), are among the primary and secondary sources referred to while preparing the Asia Pacific cell and gene therapy market report.

Reasons to Buy

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the Asia Pacific Cell and Gene Therapy market.
Highlights key business priorities in order to assist companies to realign their business strategies
The key findings and recommendations highlight crucial progressive industry trends in the Asia Pacific Cell and Gene Therapy market, thereby allowing players across the value chain to develop effective long-term strategies
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
Scrutinize in-depth Asia Pacific Cell and Gene Therapy market trends and outlook coupled with the factors driving the market, as well as those hindering it.
Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing and distribution

Table of Contents

229 Pages
1. Introduction
1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Insights
3. Research Methodology
3.1 Secondary Research
3.2 Primary Research
3.2.1 Hypothesis formulation:
3.2.2 Macro-economic factor analysis:
3.2.3 Developing base number:
3.2.4 Data Triangulation:
3.2.5 Country level data:
4. Asia Pacific Cell and Gene Therapy Market Landscape
4.1 Overview
4.2 Value Chain Analysis
4.2.1 Cell and Gene Therapy Market – Value Chain Analysis
4.2.2 Raw Material Suppliers / Components
4.2.3 Manufacturers Process / Technology
4.2.4 Distribution Landscape
4.2.5 End User
4.2.6 Level of Integration
4.3 Supply Chain Analysis
4.3.1 List of Service Providers
4.3.2 List of Potential Customers
4.4 Porter’s Five Force Analysis
4.4.1 Bargaining Power of Suppliers:
4.4.2 Bargaining Power of Buyers:
4.4.3 Threat of New Entrants
4.4.4 Threat of Substitutes:
4.4.5 Competitive Rivalry:
4.5 PEST Analysis
4.6 Impact of Artificial Intelligence (AI)
4.7 Product/Technology Roadmap
4.8 Sustainability and ESG Trends
4.8.1 Environmental Trends
4.8.2 Social Trends
4.8.3 Governance Trends
4.9 Patent Analysis
4.10 Regulatory Framework and Pipeline Analysis
4.10.1 Pipeline Analysis
4.11 Import-Export Analysis
5. Competitive Landscape
5.1 Heat Map Analysis by Key Players
5.2 Company Market Share Analysis, 2024
5.3 Company Market Share Analysis by Top 5 Players, 2024
6. Asia Pacific Cell and Gene Therapy Market – Key Market Dynamics
6.1 Asia Pacific Cell and Gene Therapy Market – Key Market Dynamics
6.2 Market Drivers
6.2.1 Increasing Prevalence of Chronic and Genetic Diseases
6.2.2 Supportive Government Initiatives
6.2.3 Rapid Popularity of Outsourcing Cell and Gene Therapy Manufacturing
6.3 Market Restraints
6.3.1 High Development and Treatment Costs
6.3.2 Complex and Lengthy Regulatory Processes
6.3.3 Shortage Of Skilled Professionals and Infrastructure
6.4 Market Opportunities
6.4.1 Strategic Initiatives by Companies
6.4.2 Expansion of Local Manufacturing Capabilities
6.4.3 Rising Investments in R&D and Clinical Trials
6.5 Future Trends
6.5.1 Surging Adoption of CRISPR and Advanced Gene Editing Technologies
6.5.2 Expansion of Non-Viral Vectors and Allogeneic Therapies
6.5.3 Integration of AI for Enhanced Efficiency in Development and Manufacturing
6.6 Impact of Drivers and Restraints:
7. Asia Pacific Cell and Gene Therapy Market Analysis
7.1 Asia Pacific Cell and Gene Therapy Market Revenue (US$ Million), 2021–2031
7.2 Asia Pacific Cell and Gene Therapy Market Forecast and Analysis
8. Asia Pacific Cell and Gene Therapy Market Analysis – by Type
8.1 Cell Therapy
8.1.1 Overview
8.1.2 Cell Therapy: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million)
8.1.2.1 Allogeneic
8.1.2.1.1 Overview
8.1.2.1.2 Allogeneic: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million)
8.1.2.2 Autologous
8.1.2.2.1 Overview
8.1.2.2.2 Autologous: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million)
8.1.2.3 Viral Vectors
8.1.2.3.1 Overview
8.1.2.3.2 Viral Vectors: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million)
8.2 Gene Therapy
8.2.1 Overview
8.2.2 Gene Therapy: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million)
8.2.2.1 Non-viral Vectors
8.2.2.1.1 Overview
8.2.2.1.2 Non-viral Vectors: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million)
8.2.2.2 Viral Vectors
8.2.2.2.1 Overview
8.2.2.2.2 Viral Vectors: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million)
9. Asia Pacific Cell and Gene Therapy Market Analysis – by Service
9.1 Process Development
9.1.1 Overview
9.1.2 Process Development: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million)
9.2 cGMP Manufacturing
9.2.1 Overview
9.2.2 cGMP Manufacturing: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million)
9.3 Regulatory Services
9.3.1 Overview
9.3.2 Regulatory Services: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million)
9.4 Bioassay Services
9.4.1 Overview
9.4.2 Bioassay Services: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million)
10. Asia Pacific Cell and Gene Therapy Market Analysis – by Scale
10.1 Pre-commercial or R and D Manufacturing
10.1.1 Overview
10.1.2 Pre-commercial or R and D Manufacturing: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million)
10.2 Commercial Scale Manufacturing
10.2.1 Overview
10.2.2 Commercial Scale Manufacturing: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million)
11. Asia Pacific Cell and Gene Therapy Market Analysis – by Service Providers
11.1 CDMOs
11.1.1 Overview
11.1.2 CDMOs: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million)
11.2 CMOs
11.2.1 Overview
11.2.2 CMOs: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million)
12. Asia Pacific Cell and Gene Therapy Market Analysis – by Transfection Reagents
12.1 Polymer-based Transfection Reagents
12.1.1 Overview
12.1.2 Polymer-based Transfection Reagents: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million)
12.2 Lipid-based Transfection Reagents
12.2.1 Overview
12.2.2 Lipid-based Transfection Reagents: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million)
12.3 Viral Transduction Enhancers
12.3.1 Overview
12.3.2 Viral Transduction Enhancers: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million)
12.4 Other Transfection Reagents
12.4.1 Overview
12.4.2 Other Transfection Reagents: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million)
13. Asia Pacific Cell and Gene Therapy Market Analysis – by End User
13.1 Contract Research Organizations
13.1.1 Overview
13.1.2 Contract Research Organizations: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million)
13.2 Pharmaceutical and Biopharmaceutical Companies
13.2.1 Overview
13.2.2 Pharmaceutical and Biopharmaceutical Companies: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million)
13.3 Academic and Research Institutes
13.3.1 Overview
13.3.2 Academic and Research Institutes: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million)
14. Asia Pacific Cell and Gene Therapy Market – Country Analysis
14.1 Asia Pacific
14.1.1 Asia Pacific Cell and Gene Therapy Market Breakdown by Countries
14.1.1.1 Asia Pacific Cell and Gene Therapy Market Breakdown by Type
14.1.1.1.1 Asia Pacific Cell and Gene Therapy Market Breakdown by Cell Therapy by Type
14.1.1.1.2 Asia Pacific Cell and Gene Therapy Market Breakdown by Gene Therapy by Type
14.1.1.2 Asia Pacific Cell and Gene Therapy Market Breakdown by Service
14.1.1.3 Asia Pacific Cell and Gene Therapy Market Breakdown by Scale
14.1.1.4 Asia Pacific Cell and Gene Therapy Market Breakdown by Service Providers
14.1.1.5 Asia Pacific Cell and Gene Therapy Market Breakdown by Transfection Reagents
14.1.1.6 Asia Pacific Cell and Gene Therapy Market Breakdown by End User
14.1.2 Asia Pacific Cell and Gene Therapy Market Revenue and Forecast and Analysis – by Country
14.1.2.1 China: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million)
14.1.2.1.1 China: Asia Pacific Cell and Gene Therapy Market Breakdown by Type
14.1.2.1.1.1 China: Asia Pacific Cell and Gene Therapy Market Breakdown by Cell Therapy by Type
14.1.2.1.1.2 China: Asia Pacific Cell and Gene Therapy Market Breakdown by Gene Therapy by Type
14.1.2.1.2 China: Asia Pacific Cell and Gene Therapy Market Breakdown by Service
14.1.2.1.3 China: Asia Pacific Cell and Gene Therapy Market Breakdown by Scale
14.1.2.1.4 China: Asia Pacific Cell and Gene Therapy Market Breakdown by Service Providers
14.1.2.1.5 China: Asia Pacific Cell and Gene Therapy Market Breakdown by Transfection Reagents
14.1.2.1.6 China: Asia Pacific Cell and Gene Therapy Market Breakdown by End User
14.1.2.2 India: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million)
14.1.2.2.1 India: Asia Pacific Cell and Gene Therapy Market Breakdown by Type
14.1.2.2.1.1 India: Asia Pacific Cell and Gene Therapy Market Breakdown by Cell Therapy by Type
14.1.2.2.1.2 India: Asia Pacific Cell and Gene Therapy Market Breakdown by Gene Therapy by Type
14.1.2.2.2 India: Asia Pacific Cell and Gene Therapy Market Breakdown by Service
14.1.2.2.3 India: Asia Pacific Cell and Gene Therapy Market Breakdown by Scale
14.1.2.2.4 India: Asia Pacific Cell and Gene Therapy Market Breakdown by Service Providers
14.1.2.2.5 India: Asia Pacific Cell and Gene Therapy Market Breakdown by Transfection Reagents
14.1.2.2.6 India: Asia Pacific Cell and Gene Therapy Market Breakdown by End User
14.1.2.3 South Korea: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million)
14.1.2.3.1 South Korea: Asia Pacific Cell and Gene Therapy Market Breakdown by Type
14.1.2.3.1.1 South Korea: Asia Pacific Cell and Gene Therapy Market Breakdown by Cell Therapy by Type
14.1.2.3.1.2 South Korea: Asia Pacific Cell and Gene Therapy Market Breakdown by Gene Therapy by Type
14.1.2.3.2 South Korea: Asia Pacific Cell and Gene Therapy Market Breakdown by Service
14.1.2.3.3 South Korea: Asia Pacific Cell and Gene Therapy Market Breakdown by Scale
14.1.2.3.4 South Korea: Asia Pacific Cell and Gene Therapy Market Breakdown by Service Providers
14.1.2.3.5 South Korea: Asia Pacific Cell and Gene Therapy Market Breakdown by Transfection Reagents
14.1.2.3.6 South Korea: Asia Pacific Cell and Gene Therapy Market Breakdown by End User
14.1.2.4 Japan: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million)
14.1.2.4.1 Japan: Asia Pacific Cell and Gene Therapy Market Breakdown by Type
14.1.2.4.1.1 Japan: Asia Pacific Cell and Gene Therapy Market Breakdown by Cell Therapy by Type
14.1.2.4.1.2 Japan: Asia Pacific Cell and Gene Therapy Market Breakdown by Gene Therapy by Type
14.1.2.4.2 Japan: Asia Pacific Cell and Gene Therapy Market Breakdown by Service
14.1.2.4.3 Japan: Asia Pacific Cell and Gene Therapy Market Breakdown by Scale
14.1.2.4.4 Japan: Asia Pacific Cell and Gene Therapy Market Breakdown by Service Providers
14.1.2.4.5 Japan: Asia Pacific Cell and Gene Therapy Market Breakdown by Transfection Reagents
14.1.2.4.6 Japan: Asia Pacific Cell and Gene Therapy Market Breakdown by End User
14.1.2.5 Singapore: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million)
14.1.2.5.1 Singapore: Asia Pacific Cell and Gene Therapy Market Breakdown by Type
14.1.2.5.1.1 Singapore: Asia Pacific Cell and Gene Therapy Market Breakdown by Cell Therapy by Type
14.1.2.5.1.2 Singapore: Asia Pacific Cell and Gene Therapy Market Breakdown by Gene Therapy by Type
14.1.2.5.2 Singapore: Asia Pacific Cell and Gene Therapy Market Breakdown by Service
14.1.2.5.3 Singapore: Asia Pacific Cell and Gene Therapy Market Breakdown by Scale
14.1.2.5.4 Singapore: Asia Pacific Cell and Gene Therapy Market Breakdown by Service Providers
14.1.2.5.5 Singapore: Asia Pacific Cell and Gene Therapy Market Breakdown by Transfection Reagents
14.1.2.5.6 Singapore: Asia Pacific Cell and Gene Therapy Market Breakdown by End User
14.1.2.6 Australia: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million)
14.1.2.6.1 Australia: Asia Pacific Cell and Gene Therapy Market Breakdown by Type
14.1.2.6.1.1 Australia: Asia Pacific Cell and Gene Therapy Market Breakdown by Cell Therapy by Type
14.1.2.6.1.2 Australia: Asia Pacific Cell and Gene Therapy Market Breakdown by Gene Therapy by Type
14.1.2.6.2 Australia: Asia Pacific Cell and Gene Therapy Market Breakdown by Service
14.1.2.6.3 Australia: Asia Pacific Cell and Gene Therapy Market Breakdown by Scale
14.1.2.6.4 Australia: Asia Pacific Cell and Gene Therapy Market Breakdown by Service Providers
14.1.2.6.5 Australia: Asia Pacific Cell and Gene Therapy Market Breakdown by Transfection Reagents
14.1.2.6.6 Australia: Asia Pacific Cell and Gene Therapy Market Breakdown by End User
14.1.2.7 Malaysia: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million)
14.1.2.7.1 Malaysia: Asia Pacific Cell and Gene Therapy Market Breakdown by Type
14.1.2.7.1.1 Malaysia: Asia Pacific Cell and Gene Therapy Market Breakdown by Cell Therapy by Type
14.1.2.7.1.2 Malaysia: Asia Pacific Cell and Gene Therapy Market Breakdown by Gene Therapy by Type
14.1.2.7.2 Malaysia: Asia Pacific Cell and Gene Therapy Market Breakdown by Service
14.1.2.7.3 Malaysia: Asia Pacific Cell and Gene Therapy Market Breakdown by Scale
14.1.2.7.4 Malaysia: Asia Pacific Cell and Gene Therapy Market Breakdown by Service Providers
14.1.2.7.5 Malaysia: Asia Pacific Cell and Gene Therapy Market Breakdown by Transfection Reagents
14.1.2.7.6 Malaysia: Asia Pacific Cell and Gene Therapy Market Breakdown by End User
14.1.2.8 Thailand: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million)
14.1.2.8.1 Thailand: Asia Pacific Cell and Gene Therapy Market Breakdown by Type
14.1.2.8.1.1 Thailand: Asia Pacific Cell and Gene Therapy Market Breakdown by Cell Therapy by Type
14.1.2.8.1.2 Thailand: Asia Pacific Cell and Gene Therapy Market Breakdown by Gene Therapy by Type
14.1.2.8.2 Thailand: Asia Pacific Cell and Gene Therapy Market Breakdown by Service
14.1.2.8.3 Thailand: Asia Pacific Cell and Gene Therapy Market Breakdown by Scale
14.1.2.8.4 Thailand: Asia Pacific Cell and Gene Therapy Market Breakdown by Service Providers
14.1.2.8.5 Thailand: Asia Pacific Cell and Gene Therapy Market Breakdown by Transfection Reagents
14.1.2.8.6 Thailand: Asia Pacific Cell and Gene Therapy Market Breakdown by End User
14.1.2.9 Philippines: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million)
14.1.2.9.1 Philippines: Asia Pacific Cell and Gene Therapy Market Breakdown by Type
14.1.2.9.1.1 Philippines: Asia Pacific Cell and Gene Therapy Market Breakdown by Cell Therapy by Type
14.1.2.9.1.2 Philippines: Asia Pacific Cell and Gene Therapy Market Breakdown by Gene Therapy by Type
14.1.2.9.2 Philippines: Asia Pacific Cell and Gene Therapy Market Breakdown by Service
14.1.2.9.3 Philippines: Asia Pacific Cell and Gene Therapy Market Breakdown by Scale
14.1.2.9.4 Philippines: Asia Pacific Cell and Gene Therapy Market Breakdown by Service Providers
14.1.2.9.5 Philippines: Asia Pacific Cell and Gene Therapy Market Breakdown by Transfection Reagents
14.1.2.9.6 Philippines: Asia Pacific Cell and Gene Therapy Market Breakdown by End User
14.1.2.10 Vietnam: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million)
14.1.2.10.1 Vietnam: Asia Pacific Cell and Gene Therapy Market Breakdown by Type
14.1.2.10.1.1 Vietnam: Asia Pacific Cell and Gene Therapy Market Breakdown by Cell Therapy by Type
14.1.2.10.1.2 Vietnam: Asia Pacific Cell and Gene Therapy Market Breakdown by Gene Therapy by Type
14.1.2.10.2 Vietnam: Asia Pacific Cell and Gene Therapy Market Breakdown by Service
14.1.2.10.3 Vietnam: Asia Pacific Cell and Gene Therapy Market Breakdown by Scale
14.1.2.10.4 Vietnam: Asia Pacific Cell and Gene Therapy Market Breakdown by Service Providers
14.1.2.10.5 Vietnam: Asia Pacific Cell and Gene Therapy Market Breakdown by Transfection Reagents
14.1.2.10.6 Vietnam: Asia Pacific Cell and Gene Therapy Market Breakdown by End User
14.1.2.11 Rest of APAC: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million)
14.1.2.11.1 Rest of APAC: Asia Pacific Cell and Gene Therapy Market Breakdown by Type
14.1.2.11.1.1 Rest of APAC: Asia Pacific Cell and Gene Therapy Market Breakdown by Cell Therapy by Type
14.1.2.11.1.2 Rest of APAC: Asia Pacific Cell and Gene Therapy Market Breakdown by Gene Therapy by Type
14.1.2.11.2 Rest of APAC: Asia Pacific Cell and Gene Therapy Market Breakdown by Service
14.1.2.11.3 Rest of APAC: Asia Pacific Cell and Gene Therapy Market Breakdown by Scale
14.1.2.11.4 Rest of APAC: Asia Pacific Cell and Gene Therapy Market Breakdown by Service Providers
14.1.2.11.5 Rest of APAC: Asia Pacific Cell and Gene Therapy Market Breakdown by Transfection Reagents
14.1.2.11.6 Rest of APAC: Asia Pacific Cell and Gene Therapy Market Breakdown by End User
15. Asia Pacific Cell and Gene Therapy Market Industry Landscape
15.1 Overview
15.2 Product Launch, Product Approvals
15.3 Expansions, Collaboration, Merger and Acquisitions, And Other Strategic Developments
16. Company Profiles
16.1 WuXi AppTec Co Ltd
16.1.1 Key Facts
16.1.2 Business Description
16.1.3 Products and Services
16.1.4 Financial Overview
16.1.5 SWOT Analysis
16.1.6 Key Developments
16.2 Lonza Group AG
16.2.1 Key Facts
16.2.2 Business Description
16.2.3 Products and Services
16.2.4 Financial Overview
16.2.5 SWOT Analysis
16.2.6 Key Developments
16.3 Syngene International Ltd
16.3.1 Key Facts
16.3.2 Business Description
16.3.3 Products and Services
16.3.4 Financial Overview
16.3.5 SWOT Analysis
16.3.6 Key Developments
16.4 Novotech
16.4.1 Key Facts
16.4.2 Business Description
16.4.3 Products and Services
16.4.4 Financial Overview
16.4.5 SWOT Analysis
16.4.6 Key Developments
16.5 SK pharmteco Inc
16.5.1 Key Facts
16.5.2 Business Description
16.5.3 Products and Services
16.5.4 Financial Overview
16.5.5 SWOT Analysis
16.5.6 Key Developments
16.6 CMIC Group
16.6.1 Key Facts
16.6.2 Business Description
16.6.3 Products and Services
16.6.4 Financial Overview
16.6.5 SWOT Analysis
16.6.6 Key Developments
16.7 Samsung Biologics Co Ltd
16.7.1 Key Facts
16.7.2 Business Description
16.7.3 Financial Overview
16.7.4 SWOT Analysis
16.7.5 Key Developments
16.8 AGC Biologics AS
16.8.1 Key Facts
16.8.2 Business Description
16.8.3 Products and Services
16.8.4 Financial Overview
16.8.5 SWOT Analysis
16.8.6 Key Developments
16.9 GenScript Biotech Corporation
16.9.1 Key Facts
16.9.2 Business Description
16.9.3 Products and Services
16.9.4 Financial Overview
16.9.5 SWOT Analysis
16.9.6 Key Developments
16.10 Porton Pharma Solutions Ltd
16.10.1 Key Facts
16.10.2 Business Description
16.10.3 Products and Services
16.10.4 Financial Overview
16.10.5 SWOT Analysis
16.10.6 Key Developments
16.11 Lotte Biologics Co Ltd
16.11.1 Key Facts
16.11.2 Business Description
16.11.3 Products and Services
16.11.4 Financial Overview
16.11.5 SWOT Analysis
16.11.6 Key Developments
16.12 Minaris Advanced Therapies
16.12.1 Key Facts
16.12.2 Business Description
16.12.3 Products and Services
16.12.4 Financial Overview
16.12.5 SWOT Analysis
16.12.6 Key Developments
16.13 Cell Therapies Pty Ltd
16.13.1 Key Facts
16.13.2 Business Description
16.13.3 Products and Services
16.13.4 Financial Overview
16.13.5 SWOT Analysis
16.13.6 Key Developments
16.14 Esco Aster Pte. Ltd.
16.14.1 Key Facts
16.14.2 Business Description
16.14.3 Products and Services
16.14.4 Financial Overview
16.14.5 SWOT Analysis
16.14.6 Key Developments
16.15 Aurigene Pharmaceutical Services
16.15.1 Key Facts
16.15.2 Business Description
16.15.3 Products and Services
16.15.4 Financial Overview
16.15.5 SWOT Analysis
16.15.6 Key Developments
16.16 GC Biopharma
16.16.1 Key Facts
16.16.2 Business Description
16.16.3 Products and Services
16.16.4 Financial Overview
16.16.5 SWOT Analysis
16.16.6 Key Developments
16.17 TEIJIN CDMO
16.17.1 Key Facts
16.17.2 Business Description
16.17.3 Products and Services
16.17.4 Financial Overview
16.17.5 SWOT Analysis
16.17.6 Key Developments
16.18 CellVec Pte Ltd
16.18.1 Key Facts
16.18.2 Business Description
16.18.3 Products and Services
16.18.4 Financial Overview
16.18.5 SWOT Analysis
16.18.6 Key Developments
16.19 Avance Clinical Pty Ltd
16.19.1 Key Facts
16.19.2 Business Description
16.19.3 Products and Services
16.19.4 Financial Overview
16.19.5 SWOT Analysis
16.19.6 Key Developments
16.20 Hilleman Laboratories
16.20.1 Key Facts
16.20.2 Business Description
16.20.3 Products and Services
16.20.4 Financial Overview
16.20.5 SWOT Analysis
16.20.6 Key Developments
17. Appendix
17.1 About The Insight Partners
17.2 Glossary of Terms
LIST OF TABLES
Table 1. Asia Pacific Cell and Gene Therapy Market Segmentation
Table 2. List of Service Providers
Table 3. List of Potential Customers
Table 4. List of Patents and Description
Table 5. List of Regulatory Bodies and Organizations
Table 6. Import-Export Value of Products Falling Under HS Code 300290: Human Blood; Animal Blood Prepared for Therapeutic, Prophylactic or Diagnostic Uses
Table 7. Heat Map Analysis by Key Players
Table 8. Company Market Share (%) Analysis by Top 5 Players, 2024
Table 9. Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million)
Table 10. Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million) – by Type
Table 11. Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million) – by Cell Therapy by Type
Table 12. Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million) – by Gene Therapy by Type
Table 13. Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million) – by Service
Table 14. Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million) – by Scale
Table 15. Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million) – by Service Providers
Table 16. Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million) – by Transfection Reagents
Table 17. Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million) – by End User
Table 18. China: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million) – by Type
Table 19. China: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million) – by Cell Therapy by Type
Table 20. China: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million) – by Gene Therapy by Type
Table 21. China: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million) – by Service
Table 22. China: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million) – by Scale
Table 23. China: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million) – by Service Providers
Table 24. China: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million) – by Transfection Reagents
Table 25. China: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million) – by End User
Table 26. India: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million) – by Type
Table 27. India: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million) – by Cell Therapy by Type
Table 28. India: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million) – by Gene Therapy by Type
Table 29. India: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million) – by Service
Table 30. India: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million) – by Scale
Table 31. India: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million) – by Service Providers
Table 32. India: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million) – by Transfection Reagents
Table 33. India: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million) – by End User
Table 34. South Korea: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million) – by Type
Table 35. South Korea: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million) – by Cell Therapy by Type
Table 36. South Korea: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million) – by Gene Therapy by Type
Table 37. South Korea: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million) – by Service
Table 38. South Korea: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million) – by Scale
Table 39. South Korea: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million) – by Service Providers
Table 40. South Korea: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million) – by Transfection Reagents
Table 41. South Korea: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million) – by End User
Table 42. Japan: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million) – by Type
Table 43. Japan: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million) – by Cell Therapy by Type
Table 44. Japan: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million) – by Gene Therapy by Type
Table 45. Japan: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million) – by Service
Table 46. Japan: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million) – by Scale
Table 47. Japan: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million) – by Service Providers
Table 48. Japan: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million) – by Transfection Reagents
Table 49. Japan: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million) – by End User
Table 50. Singapore: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million) – by Type
Table 51. Singapore: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million) – by Cell Therapy by Type
Table 52. Singapore: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million) – by Gene Therapy by Type
Table 53. Singapore: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million) – by Service
Table 54. Singapore: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million) – by Scale
Table 55. Singapore: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million) – by Service Providers
Table 56. Singapore: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million) – by Transfection Reagents
Table 57. Singapore: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million) – by End User
Table 58. Australia: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million) – by Type
Table 59. Australia: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million) – by Cell Therapy by Type
Table 60. Australia: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million) – by Gene Therapy by Type
Table 61. Australia: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million) – by Service
Table 62. Australia: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million) – by Scale
Table 63. Australia: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million) – by Service Providers
Table 64. Australia: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million) – by Transfection Reagents
Table 65. Australia: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million) – by End User
Table 66. Malaysia: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million) – by Type
Table 67. Malaysia: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million) – by Cell Therapy by Type
Table 68. Malaysia: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million) – by Gene Therapy by Type
Table 69. Malaysia: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million) – by Service
Table 70. Malaysia: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million) – by Scale
Table 71. Malaysia: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million) – by Service Providers
Table 72. Malaysia: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million) – by Transfection Reagents
Table 73. Malaysia: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million) – by End User

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us